EUVIMEDEUVIMED entdecken
Übersichtsarbeit

From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer

Xinyi Ding, Hao Huang, Zhang Fang, Jingting Jiang

Current Treatment Options in Oncology · 2024-12 · 25 (12) · 1580-1593

DOI: 10.1007/s11864-024-01282-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 26.11.2024. Verfasst von Xinyi Ding und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu Province, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Precision Medicine, Biomarkers, Tumor. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: The National Natural Science Foundation of China, Changzhou social development science and technology support project, Jiangsu Funding Program for Excellent Postdoctoral Talent.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: The biological heterogeneity of colorectal cancer makes its molecular characteristics essential for therapeutic decision-making and prognostic evaluation. Recent advancements in consensus molecular subtyping, based on gene expression profiling, have provided deeper insights into the heterogeneity of CRC. CMS1, known as the immune subtype, is characterized by robust immune activity and microsatellite instability. CMS2, the canonical subtype, exhibits significant activation of the WNT and MYC signaling pathways. CMS3, the metabolic subtype, features unique metabolic dysregulations. CMS4, the mesenchymal subtype, is recognized for its stromal invasion and angiogenesis, which are associated with a poorer prognosis. This review delivers a thorough analysis of the biological and clinical responses of each CMS subtype in colorectal cancer, highlighting their therapeutic vulnerabilities. It integrates data and clinical trial results to suggest potential new therapies for each subtype. The goal is to improve therapeutic efficacy, minimize treatment disparities, and offer CRC patients more precise treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsPrecision MedicineBiomarkers, TumorHumansPrognosisMolecular Targeted TherapyGene Expression ProfilingDisease ManagementMicrosatellite InstabilityDisease SusceptibilityGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Biological HeterogeneityClinical HeterogeneityColorectal cancerConsensus Molecular SubtypesTherapy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu Province, China.
  • Jiangsu Engineering Research Center for Tumor Immunotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
  • Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
  • Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu Province, China. jiangjingting@suda.edu.cn.
  • Jiangsu Engineering Research Center for Tumor Immunotherapy, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China. jiangjingting@suda.edu.cn.
  • Institute of Cell Therapy, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China. jiangjingting@suda.edu.cn.

Förderung

  • The National Natural Science Foundation of China
  • Changzhou social development science and technology support project
  • Jiangsu Funding Program for Excellent Postdoctoral Talent
  • the Key R&D Project of Jiangsu Province

Zitieren

APA

Ding, X., Huang, H., Fang, Z., & Jiang, J. (2024). From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer. Current Treatment Options in Oncology, 25(12), 1580-1593. https://doi.org/10.1007/s11864-024-01282-5

Vancouver

Ding X, Huang H, Fang Z, Jiang J. From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer. Current Treatment Options in Oncology. 2024;25(12):1580-1593. doi:10.1007/s11864-024-01282-5

BibTeX
@article{Ding2024,
  author = {Ding, Xinyi and Huang, Hao and Fang, Zhang and Jiang, Jingting},
  title = {From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  volume = {25},
  number = {12},
  pages = {1580--1593},
  doi = {10.1007/s11864-024-01282-5}
}
Kostenlos starten →